Compare ADMA Biologics Inc (ADMA) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs 22nd Century Group Inc — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while 22nd Century Group Inc trades at $4.33 (market cap $1.52M). The key difference: ADMA Biologics Inc is far larger — about 1460.5× 22nd Century Group Inc's market cap, and ADMA Biologics Inc is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | XXII | |
|---|---|---|
Market Cap | $2.22B | $1.52M |
Sector | Health | Technology |
52-Week High | $20.38 | $801.00 |
52-Week Low | $7.60 | $3.72 |
Enterprise Value | $2.29B | -$6.71M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.83, up 0.82% today, with strong profitability metrics including a 32.98% net income margin and 41.9% ROE. Recent earnings show mixed results, with a beat in Q4 2025 but misses in Q1 and Q2 2026. Technical indicators are bullish overall, though RSI levels suggest overbought conditions. The stock faces significant legal headwinds from multiple securities fraud class actions filed in August 2026.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but legal risks and recent earnings misses pose near-term challenges. Upside potential exists if the company can maintain profitability and resolve litigation, while downside risks include prolonged legal proceedings and execution missteps.
XXII trades at $4.38, up 0.69% with neutral technical signals. The company shows concerning fundamentals with negative profit margins (-65.76% net income margin) and ROE of -130.19%, though valuation ratios appear low (P/S 0.03, P/B 0.07). Recent corporate actions include a 20:1 reverse stock split in June 2026. Analyst sentiment remains positive with 75% buy ratings, while the company expands VLN® product distribution in key markets like California and New York.
The outlook remains speculative given persistent losses despite revenue generation. Investment opportunity lies in successful execution of reduced-nicotine cigarette expansion and FDA regulatory progress. Key risks include continued cash burn, competitive pressures, and dependency on regulatory approvals for growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
